Objective We provide new information about how the risk of adverse events following colonoscopy varies by age and indication (screening vs. follow-up performed to evaluate a positive result from another screening modality). Methods We constructed a retrospective cohort comprised of 43,456 individuals aged 40-85 years enrolled in a large integrated healthcare organization in Washington State who underwent outpatient colonoscopy between 1994 and 2009. We calculated rates of serious adverse events (perforation, hemorrhage, and acute diverticulitis) in the 30 days following colonoscopy and compared rates using log-binomial regression models. Results We observed 4.7 serious adverse events per 1,000 screening colonoscopies and 6.8 per 1,000 follow-up colonoscopies. Polypectomy increased the rate of serious adverse events (relative rate [RR], 2.64; 95% confidence interval [CI], 1.97-3.56). Older age was associated with increased risk of serious adverse events, after adjusting for polypectomy, gender, and indication. Compared to individuals aged 50-64 years, risk was elevated for those aged 65-74 (RR, 1.93; 95% CI, 1.40-2.65) and 75-85 (RR, 3.21; 95% CI 2.14-4.86). We observed similar age effects in individuals with and without significant comorbid conditions. Conclusions The risks of serious adverse events following colonoscopy performed as part of screening are low but increase with age and are more likely after polypectomy.
Introduction
There is little debate that colorectal cancer (CRC) screening in individuals aged 50-75 years reduces CRC mortality [1] [2] [3] [4] [5] , with approximately half of the recent decline in CRC incidence attributed to screening [6] . Colonoscopy can prevent CRC through detection and removal of adenomas, and the use of colonoscopy for screening is increasing [7] [8] [9] . However, serious complications can follow colonoscopy including death, hospitalization, perforation, major bleeding, diverticulitis, cardiovascular events, and/or serious abdominal pain [3, [10] [11] [12] [13] . Because complications are rare, their study requires the use of large datasets allowing estimation of adverse events following colonoscopy, which includes both events directly related to colonoscopy (complications) and other coincidental events.
Studies examining risks of adverse events following colonoscopy have not distinguished between the four main indications for colonoscopy, which are screening of asymptomatic individuals with no clinical indications of CRC, follow-up for evaluation of positive results from another CRC screening test, diagnostic work-up for evaluation of symptoms, and surveillance of individuals with a history of colorectal adenomas. Instead, analyses have estimated rates of adverse events following colonoscopy by combining screening, follow-up, and diagnostic colonoscopy. Separating risk by screening indication is important, because although the expected benefit is greater among individuals undergoing diagnostic, surveillance, or followup examinations than those receiving screening examinations, the risks may be higher from an increased chance of polypectomy. Thus, screening colonoscopy risks may be overestimated by studies that include data from diagnostic colonoscopy.
CRC screening in individuals aged 50-75 years reduces CRC mortality [1] [2] [3] [4] [5] , and average-risk individuals are recommended to begin CRC screening at age 50. After Medicare began covering screening colonoscopy in 2001, the use of screening colonoscopy rapidly increased, with a corresponding decrease in fecal occult blood testing and flexible sigmoidoscopy [7] . However, this has occurred in the absence of sufficient evidence on screening colonoscopy risks that would help individuals make informed, shared decisions with their providers about CRC screening modalities. To address this evidence gap, we used data from a large population-based cohort to examine adverse event rates, stratified by age, following colonoscopy performed for screening or to follow-up a screening assessment. Our results offer a more detailed analysis of screening colonoscopy risks.
Methods
This retrospective cohort study included individuals of 40-85 years old who had an outpatient screening or followup colonoscopy between 1994 and 2009 at a large, nonprofit, consumer-governed health care system in Washington State that integrates care and coverage for over 600,000 members. Between 1997 and 2010, the preferred screening option for average-risk individuals was Hemoccult SENSA (Beckman Coulter, Fullerton, California) in conjunction with flexible sigmoidoscopy. Colonoscopy was covered as a screening modality in 2001, when Medicare began coverage for screening colonoscopy [14, 15] .
Colonoscopies
We focused on risk following screening and follow-up colonoscopy, performed in an outpatient community setting. To be included in the sample, we required individuals to have at least 6 months of continuous enrollment prior to a colonoscopy and enrollment for 30 days after the examination unless the subject died during this period. When individuals had multiple examinations, we included only the first eligible colonoscopy.
We used automated data in combination with four criteria to exclude diagnostic colonoscopies, that is, examinations carried out to evaluate symptoms. First, we excluded colonoscopy codes associated with diagnostic procedures: endoscopic hemostasis of a bleeding colonic lesion, insertion of a colonic stent, endoscopic colonic dilatation, and endoscopic reduction of a sigmoid volvulus [16] . Second, we excluded colonoscopies in individuals with a visit in the 6 months prior to colonoscopy that resulted in a diagnosis associated with gastrointestinal or colorectal cancer symptoms, including diarrhea, abdominal pain, gastrointestinal bleeding, and anemia. Third, we excluded colonoscopies in individuals who had an upper endoscopy in the 7 days before colonoscopy, as this suggests that the colonoscopy was part of a diagnostic evaluation, and individuals with abdominal imaging in the 90 days prior to colonoscopy, in whom incidental findings may have lead to follow-up diagnostic colonoscopy. Fourth, we excluded colonoscopies with a negative fecal occult blood test in the prior 6 months as potentially diagnostic. We were unable to exclude based on prior results from barium enema or flexible sigmoidoscopy, because this information is not captured within available utilization data. We excluded individuals with a prior diagnosis of inflammatory bowel disease, ulcerative colitis, or Crohn's disease because colonoscopy may guide treatment in these patients (rather than being used specifically for CRC screening) [17] and these patients are at increased risk for CRC [18, 19] . We also excluded individuals who underwent colonoscopies after colonic resection or diagnosis with any non-melanoma cancer because these individuals were not eligible for usual screening for incident CRC.
Follow-up colonoscopies were defined by receipt of another CRC screening test (fecal occult blood tests, flexible sigmoidoscopy, or barium enema) in the prior 6 months. We used procedure codes to categorize colonoscopies as with or without polypectomy based on indications of either polypectomy or biopsy as part of the procedure (biopsy: CPT 45380; polypectomy: CPT 45383, 45384, 45385 and ICD9 45.43, 48.36). We also used procedure codes to identify use of ''hot'' procedures that use cautery to simultaneously remove and electrocoagulate tissue, to explore whether the use of heat was associated with increased risk for complications (such as abdominal pain that may be associated with serosal burns). Codes used in our inclusion and exclusion criteria are included in the ''Appendix.'' Outcomes: adverse events We examined adverse events occurring within 30 days after the index colonoscopy. Outcomes examined were death, hospitalization, perforation, hemorrhage, acute incident diverticulitis (ICD9 562.11 and 562.13), dehydration, and abdominal pain, identified using ICD-9 codes. We also examined acute-care utilization during the 30 days after colonoscopy, including hospitalization and emergency department and urgent care visits. Hospitalizations excluded individuals with CRC detected within 2 months of the colonoscopy, to avoid inclusion of hospitalizations associated with cancer care.
Statistical analysis
We describe overall rates of serious adverse events following screening colonoscopy and compare rates by age group, indication (screening or follow-up), polypectomy (yes/no), and Klabunde comorbidity score [20] using logbinomial regression models that adjust for relevant covariates (e.g., models that examine the effect of age on complication rates adjusted for polypectomy and examination year). All regression models included at least 20 events per predictor. The Klabunde comorbidity score uses diagnostic and procedure codes to identify individuals who may have comorbid conditions that place them at increased risk for death in the following 2 years.
Results
We identified 158,295 colonoscopies performed between 1994 and 2009. Of these, 43,515 (29%) of procedures in 43,456 patients met the study criteria as likely screening or follow-up colonoscopies. In this 16-year window, most individuals included in our cohort (99.9%) had only one colonoscopy.
The number of screening colonoscopies increased sharply over time, reflecting changes in screening recommendations and uptake, while the number of follow-up colonoscopies was stable (Table 1) The age of individuals undergoing a screening or follow-up colonoscopy decreased over the study period, from Serious adverse events were more likely after polypectomy (unadjusted rates of 2.7 per 1,000 without polypectomy and 7.4 per 1,000 with polypectomy). The estimated rate of serious adverse events following colonoscopy with polypectomy relative to colonoscopy without polypectomy was 2.64 (95% CI, 1.97-3.56), based on a model that adjusted for gender, indication (screening or follow-up), and age at procedure. We found no evidence of secular changes in adverse event rates following colonoscopy (1994) (1995) (1996) (1997) 03-1.90) , based on models that adjusted for age, gender, polypectomy, and examination indication. We found no evidence for secular trends in the rate of polypectomy. Table 2 describes specific adverse events following colonoscopy overall, by examination indication, and with or without polypectomy. Of individuals with at least one adverse event, only 16% had multiple events. Abdominal pain was the most common co-occurring adverse event, identified in 29% of individuals with perforation, 18% of individuals with hemorrhage, 28% of individuals with incident diverticulitis, and 17% of individuals with urgent care visits. Abdominal pain was also the most common adverse event overall (25.9 per 1,000), although abdominal pain associated with a same-day hospitalization was rare (0.3 per 1,000 colonoscopies). Dehydration was only rarely indicated in ICD-9 codes (1.1 per 1,000 colonoscopies).
We observed 15 deaths in the 30 days following colonoscopy, corresponding to 0.3 deaths per 1,000 colonoscopies. However, in 8 of 15 people with cause-of-death information, none were attributed to perforation or colonoscopy complications. Perforation was also rare, occurring in 0.5 per 1,000 colonoscopies, with higher rates among those with polypectomy than those without (0.6 vs. 0.3 per 1,000). Hemorrhage was more common than perforation and, like perforation, occurred more often among those with polypectomy than those without. Table 3 shows adverse events in the 30 days following screening colonoscopy by age. Subsequent diagnoses of abdominal pain were most common in the youngest age group (6.4% of colonoscopies in 40-to 49-year olds versus 2.2-3.5% in the older age groups). Older age was associated with higher rates of perforation, and hemorrhage, and subsequent diagnosis of diverticulitis. Overall, older age was associated with a higher rate of serious adverse events: 4.2 per 1,000 for ages 40-49, 3.7 per 1,000 for ages 50-64, 7.9 per 1,000 for ages 65-74, and 13.3 per 1,000 for ages 75-84. Across age groups, the estimated relative rate of serious adverse events following colonoscopy, compared to 50-to 64-year olds, was (with 95% CIs) 1.07 (0.58- 
Discussion
This study adds to our knowledge about the risks of adverse events following screening colonoscopies, including detailed estimates of adverse event rates in individuals between the ages of 40 and 64, when many people initiate CRC screening. Adverse event rates were similar among individuals undergoing screening and follow-up colonoscopy after adjusting for polypectomy. However, the rate of serious adverse events (perforation, hemorrhage, and diverticulitis) increased with age, even after adjusting for polypectomy. While adverse events remained unlikely, particularly in younger age groups, the risk of serious adverse events was three times higher among 75-to 84-year olds compared to 50-to 64-year olds. This increased potential risk of colonoscopy complications must be balanced against an individual's potential benefit from CRC detection and prevention. While individuals over 75 are at increased risk for incident CRC compared to younger individuals, the potential benefit from primary prevention due to adenoma removal may be reduced, given the remaining life expectancy.
Our results parallel findings from Warren and colleagues [12] , who used a matched cohort study of Medicare beneficiaries of 66 years and older to examine the risk of serious adverse events following colonoscopy performed from 2001 to 2005. They found that individuals who underwent screening or diagnostic colonoscopy were at increased risk of serious gastrointestinal (GI) events (perforation, gastrointestinal bleeding, administration of blood transfusions), reporting 6.9 serious GI events per 1,000 screening and diagnostic colonoscopies, and 2.4 serious GI events per 1,000 screening colonoscopies without polypectomy. However, age effects may be related to pre-procedure warfarin use [13] . Changes in colonoscopy risk with age are particularly important given the increased use of colonoscopy as a screening modality [7] [8] [9] . In their 2008 screening guidelines, the US Preventive Services Task Force recommended against routine screening in individuals older than 85 years, noting that ''the benefits of detection and early intervention decline after age 75 years'' because of competing causes of mortality [4] . Guidelines issued by the US Multi-Society Task Force [2] and the American College of Gastroenterology [5] do not address upper age limits for CRC screening, and no guidelines discuss how the riskbenefit trade-off for different screening modalities shifts as an individual ages. Future studies should consider whether a less invasive test, such as fecal occult blood tests, may provide benefit with fewer risks in individuals over age 75.
Our overall rate of adverse events, 4.7 per 1,000 screening colonoscopies, was somewhat higher than previous reports on adverse events following colonoscopy. However, these earlier studies did not distinguish between screening, follow-up, diagnostic, and surveillance colonoscopies and analyzed data from periods when screening colonoscopy was relatively less common. A 2008 metaanalysis estimated 2.8 serious adverse events per 1,000 colonoscopies (95% CI, 1.5-5.2), where serious adverse events included death, hospitalization, perforation, major bleeding, diverticulitis, cardiovascular events, and/or serious abdominal pain [3] . Singh and colleagues [11] estimated 2.9 serious complications per 1,000 colonoscopies between 2004 and 2006 in a Canadian sample, using chart review to examine a broad range of complications including acute myocardial infarctions, renal failure, dehydration, intestinal obstruction, episodes of pneumonia and acute diverticulitis, severe abdominal pain, hemorrhage, and perforation. Based on surveys of patients who had undergone screening or diagnostic colonoscopy, Ko and colleagues estimated only 2.0 complications per 1,000 colonoscopies [13] .
Consistent with the previous studies, we found that serious adverse events were more likely following polypectomy. Although adenoma prevalence increases with age [21] , the proportion of colonoscopies with polypectomy did not increase strongly with age, ranging from 43% to 52%. This may be attributable to differential screening test selection: 50-to 64-year olds had both the highest rate of follow-up colonoscopy and the highest rate of colonoscopy with polypectomy. The percentage of colonoscopies with polypectomy may also be higher in younger members of our cohort than would be expected for the general population if individuals with a family history of CRC were more likely to be screened at earlier ages. In addition, the percentage of colonoscopies with polypectomy may be lower in older members of our cohort than would be expected in a prevalence screening study if some individuals had previously undergone colonoscopy either outside of the study period or outside of the delivery system.
Our study has several limitations. We relied on procedure and diagnosis codes to determine the indication for colonoscopy and occurrence of events linked to colonoscopy. This could result in inclusion of some events that were not a direct result of colonoscopy. Because we did not carry out a chart review, we focused on events that are likely to be associated with colonoscopy and did not consider outcomes such as cardiovascular events that may or may not be linked to colonoscopy. For example, we did not examine cardiopulmonary events that are related to sedation during colonoscopy [22] . Another limitation is our use of procedure and laboratory data to determine indication for colonoscopy. Through extensive exclusion criteria, we aimed to include only screening and follow-up colonoscopies at the expense of misclassifying some examinations as diagnostic. However, it is possible that some diagnostic examinations were included. In addition, we did not specifically exclude colonoscopies resulting from adenoma surveillance, though we only included the first examination. Some misclassification of screening and follow-up colonoscopies may also have occurred, for example, individuals seeking follow-up after an outside screening test without an associated claim record would be misclassified as screening colonoscopy. Focusing on first examinations may limit the generalizability of our findings, if adverse event rate are systematically higher (or lower) for subsequent examinations. We relied on procedure codes to determine the use of electrocautery, so it is possible that we did not fully capture these procedures. We also had limited ability to examine mechanisms that may drive age effects, although we found that among individuals without significant comorbid conditions, older individuals continued to be at greater risk for complications following screening colonoscopy. Specifically, we were unable to adjust for pre-examination medication use, which likely increases with age, even among those without serious complications. While we could have examined pre-examination prescriptions for warfarin, we could not provide conclusive results because we could not determine temporary cessation in medications or capture use of non-prescription medications (nonsteroidal anti-inflammatory drugs) associated with increased risk of bleeding. Similarly, we could not adjust for the number or size of lesions removed. The number of adenomas removed is likely to increase with age, and the risk for serious adverse events is likely to increase with each polypectomy. Similarly, removal of larger adenomas may carry greater risk than removal of smaller adenomas, and older individuals may be more likely to have large adenomas.
Our study provides new information about adverse events following screening and follow-up colonoscopy, both overall and among individuals of 40 to 64 years old, and adds to the general evidence about adverse events following colonoscopy. Rates of serious adverse events are rare, especially among younger individuals. These immediate risks are balanced by the longer term benefits of decreased risk for CRC. Overall, our results are reassuring for individuals considering a first screening colonoscopy at age 50.
